S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

MESO Mesoblast Limited

7.55

0.26 (3.57%)

04 May 2024 - Closed

Delayed by 15 minutes

Mesoblast announces data from Phase 3 study in chronic back pain

To read the full story on Seeking Alpha, click here.

Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Mesoblast Charts.

Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Mesoblast Charts.

Mesoblast Limited News

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
Tuesday 30 April 2024 (6 days ago) • GlobeNewswire Inc.

FDA Commentary Sends Biotech Soaring During Premarket Hours
Wednesday 27 March 2024 (1 month ago) • AllPennyStocks.com

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Tuesday 26 March 2024 (1 month ago) • GlobeNewswire Inc.

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
Thursday 14 March 2024 (2 months ago) • GlobeNewswire Inc.

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
Monday 11 March 2024 (2 months ago) • GlobeNewswire Inc.

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
Thursday 29 February 2024 (2 months ago) • GlobeNewswire Inc.

Mesoblast Financial Results and Corporate Update Webcast
Monday 26 February 2024 (2 months ago) • GlobeNewswire Inc.

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
Thursday 15 February 2024 (3 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 1 February 2024 (3 months ago) • Edgar (US Regulatory)

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
Wednesday 31 January 2024 (3 months ago) • GlobeNewswire Inc.

Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment
Friday 19 January 2024 (4 months ago) • Dow Jones News

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
Friday 19 January 2024 (4 months ago) • GlobeNewswire Inc.

More Mesoblast Limited News Articles

Sterling vs AUD

JP Morgan Chase

Australian SE All Ordina...

Woodside Petroleum

Westpac Banking

AUD vs US Dollar

Verizon Communications

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions